T3165 - Naloxone, 4Mg Nasal Spray, Fda-Approved, for the New Jersey Department of Human Services
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
Division of Purchase and Property
Contract Value
Not provided
Codes & Classification
Solicitation Number
26DPP01283
NAICS
-
Classification Code
-
Additional Details
The New Jersey Department of Human Services, through the Division of Purchase and Property, has issued a procurement notice (Procurement Identifier: 26DPP01283) seeking qualified vendors to supply FDA-approved Naloxone 4mg nasal spray. This initiative is designed to support the Department’s ongoing efforts to address opioid overdoses across the state by ensuring the availability of this critical, life-saving medication.
The scope of this procurement encompasses the provision and delivery of Naloxone nasal spray in the specified 4mg dosage form. The product must be FDA-approved, ensuring compliance with all relevant safety and efficacy standards. The primary objective is to secure a reliable supply chain for Naloxone, enabling the Department of Human Services to distribute the medication as needed to various programs, agencies, or partners involved in overdose prevention and response throughout New Jersey.
Key requirements for this opportunity include the ability to provide Naloxone nasal spray that meets all FDA approval criteria, as well as adherence to any state-specific regulations governing the distribution of such medication. Vendors are expected to demonstrate capacity for timely delivery and consistent supply, as these factors are critical to the success of the Department’s public health initiatives.
The contracting entity for this procurement is the Division of Purchase and Property, a state-level organization responsible for managing large-scale acquisitions on behalf of New Jersey government agencies. All activities related to this procurement will be conducted within the state of New Jersey.
Interested contractors should note that the notice was posted on August 19, 2026, with responses due by October 27, 2026. The procurement is being managed through the NJSTART system, and all relevant documents and submission instructions are available via the official bid portal (https://www.njstart.gov/bso/external/bidDetail.sda?docId=26DPP01283&external=true&parentUrl=close). While the notice does not specify set-aside requirements or special considerations, contractors are encouraged to review all provided documentation for detailed terms and conditions.
This procurement represents a significant opportunity for suppliers of FDA-approved Naloxone nasal spray to partner with the State of New Jersey in advancing public health and safety. Contractors with proven experience in pharmaceutical supply, particularly in the area of opioid overdose reversal agents, are well-positioned to respond to this solicitation.
Documents10